Do Flexeril (cyclobenzaprine) and Baclofen share the same primary mechanism of action?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mechanism of Action Comparison: Flexeril vs Baclofen

No, Flexeril (cyclobenzaprine) and baclofen do not share the same primary mechanism of action—cyclobenzaprine is structurally identical to amitriptyline and acts through central anticholinergic and sedative effects without true muscle relaxation, while baclofen is a GABA-B receptor agonist that acts specifically at the spinal level to reduce neurotransmitter release and inhibit reflex arcs. 1

Cyclobenzaprine (Flexeril) Mechanism

  • Cyclobenzaprine is essentially identical to the tricyclic antidepressant amitriptyline and does not directly relax skeletal muscle despite being marketed as a "muscle relaxant." 1

  • The drug's effects are nonspecific and not related to actual muscle relaxation—it may inhibit polysynaptic myogenic reflexes in animal models, but whether this relates to pain relief in humans remains unknown. 1

  • Cyclobenzaprine and other so-called muscle relaxants (carisoprodol, chlorzoxazone, metaxalone, methocarbamol) have no evidence of efficacy in chronic pain and should not be prescribed believing they relieve muscle spasm. 1

  • These agents carry potential adverse effects similar to tricyclic antidepressants, including sedation, anticholinergic effects, and increased fall risk in older adults. 1

Baclofen Mechanism

  • Baclofen is a GABA-B receptor agonist that works through a completely different mechanism than cyclobenzaprine. 1

  • It activates GABA-B receptors located on primary afferent terminals, which retards calcium ion influx into nerve terminals and reduces the evoked release of excitatory amino acids and other neurotransmitters. 2

  • Baclofen is classified as a centrally acting spasmolytic agent with documented spinal action—it acts at the spinal level to suppress the excitability of spinal pathways to muscle motoneurons. 1

  • The drug has documented efficacy for spasticity from upper motor neuron syndromes (multiple sclerosis, spinal cord injury) through genuine reduction of velocity-dependent muscle tone. 3, 4

Clinical Implications

  • If true muscle spasm is suspected, baclofen is the appropriate choice rather than cyclobenzaprine or other "muscle relaxants" that lack specific antispasmodic mechanisms. 1

  • Baclofen should be continued perioperatively (including the day of surgery) due to risk of serious withdrawal symptoms including hallucinations, seizures, and potentially life-threatening complications with abrupt discontinuation. 1

  • Both agents increase sedation risk when combined with opioids or CNS depressants, but through different mechanisms—cyclobenzaprine through anticholinergic/tricyclic effects and baclofen through GABA-B agonism. 1

  • In older adults, baclofen carries higher fall risk than tizanidine (another alpha-2 agonist) but comparable risk to cyclobenzaprine, with baclofen causing more weakness as a side effect. 3, 5

Key Distinction

The fundamental difference is that baclofen has a specific, well-defined mechanism (GABA-B receptor agonism) with proven efficacy for true spasticity, while cyclobenzaprine is a tricyclic compound with nonspecific central effects that does not actually relax muscle. 1, 3, 2 They are grouped together as "muscle relaxants" by convention and FDA classification, but this categorization is misleading regarding their actual pharmacological actions.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Antispasticity drugs: mechanisms of action.

Annals of neurology, 1985

Research

Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1988

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.